pentoxifylline has been researched along with MODS in 16 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "Pentoxifylline protects against sepsis-induced microcirculatory derangement in neonates." | 9.14 | Effects of pentoxifylline on coagulation profile and disseminated intravascular coagulation incidence in Egyptian septic neonates. ( Abdel-Naim, AB; Adel, M; Al-Azizi, MM; Awad, HA, 2010) |
| "To evaluate the effect of pentoxifylline on organ dysfunction, survival, and mediator response in patients with severe sepsis." | 9.08 | Effect of pentoxifylline in severe sepsis: results of a randomized, double-blind, placebo-controlled study. ( Gehrke, K; Schröder, J; Staubach, KH; Stüber, F; Traumann, E; Zabel, P, 1998) |
| "We assessed the safety and efficacy of intravenous pentoxifylline [3,7-dimethyl-1-(5-oxohexyl)-xanthine] in patients at risk for developing multiple organ failure after major cardio-thoracic surgery in a single-center, randomized, placebo-controlled study." | 9.08 | Pentoxifylline decreases the incidence of multiple organ failure in patients after major cardio-thoracic surgery. ( Faist, E; Hoffmann, H; Jochum, M; Kreuzer, E; Markewitz, A; Reichert, K, 1998) |
| "Data presented showed that pentoxifylline attenuates microcirculatory disturbances at the mesenteric bed with significant minimization of lung inflammation after a double-injury model of hemorrhagic shock and reperfusion followed by sepsis." | 7.81 | Pentoxifylline attenuates leukocyte-endothelial interactions in a two-hit model of shock and sepsis. ( Aikawa, P; Correia, CJ; Cruz, JW; Cruz, RJ; Mauad, T; Nakagawa, NK; Rocha-e-Silva, M; Sannomiya, P; Zhang, H, 2015) |
| "Pentoxifylline protects against sepsis-induced microcirculatory derangement in neonates." | 5.14 | Effects of pentoxifylline on coagulation profile and disseminated intravascular coagulation incidence in Egyptian septic neonates. ( Abdel-Naim, AB; Adel, M; Al-Azizi, MM; Awad, HA, 2010) |
| "To evaluate the effect of pentoxifylline on organ dysfunction, survival, and mediator response in patients with severe sepsis." | 5.08 | Effect of pentoxifylline in severe sepsis: results of a randomized, double-blind, placebo-controlled study. ( Gehrke, K; Schröder, J; Staubach, KH; Stüber, F; Traumann, E; Zabel, P, 1998) |
| "We assessed the safety and efficacy of intravenous pentoxifylline [3,7-dimethyl-1-(5-oxohexyl)-xanthine] in patients at risk for developing multiple organ failure after major cardio-thoracic surgery in a single-center, randomized, placebo-controlled study." | 5.08 | Pentoxifylline decreases the incidence of multiple organ failure in patients after major cardio-thoracic surgery. ( Faist, E; Hoffmann, H; Jochum, M; Kreuzer, E; Markewitz, A; Reichert, K, 1998) |
| "Data presented showed that pentoxifylline attenuates microcirculatory disturbances at the mesenteric bed with significant minimization of lung inflammation after a double-injury model of hemorrhagic shock and reperfusion followed by sepsis." | 3.81 | Pentoxifylline attenuates leukocyte-endothelial interactions in a two-hit model of shock and sepsis. ( Aikawa, P; Correia, CJ; Cruz, JW; Cruz, RJ; Mauad, T; Nakagawa, NK; Rocha-e-Silva, M; Sannomiya, P; Zhang, H, 2015) |
| "To investigate the effects of pentoxifylline (PTX) administration in a murine model for the multiple-organ dysfunction syndrome (MODS)." | 3.73 | Pentoxifylline does not improve outcome in a murine model for the multiple-organ dysfunction syndrome. ( Goris, RJ; Hendriks, T; Volman, TJ, 2005) |
| "Pentoxifylline is a phosphodiesterase inhibitor, known to suppress tumour necrosis factor-alpha production and improve cardiopulmonary parameters and survival in animal models of sepsis." | 1.31 | Pentoxifylline fails to improve organ dysfunction and survival when used in the resuscitation of a porcine model of haemorrhage and abdominal sepsis. ( Brown, D; Kenward, CE; Parker, SJ; Watkins, PE, 2000) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (6.25) | 18.7374 |
| 1990's | 8 (50.00) | 18.2507 |
| 2000's | 5 (31.25) | 29.6817 |
| 2010's | 2 (12.50) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Nakagawa, NK | 1 |
| Cruz, RJ | 1 |
| Aikawa, P | 1 |
| Correia, CJ | 1 |
| Cruz, JW | 1 |
| Mauad, T | 1 |
| Zhang, H | 1 |
| Rocha-e-Silva, M | 1 |
| Sannomiya, P | 1 |
| Adel, M | 1 |
| Awad, HA | 1 |
| Abdel-Naim, AB | 1 |
| Al-Azizi, MM | 1 |
| Schröder, J | 2 |
| Staubach, KH | 2 |
| Stüber, F | 2 |
| Zabel, P | 2 |
| Volman, TJ | 1 |
| Goris, RJ | 1 |
| Hendriks, T | 1 |
| Marshall, JC | 1 |
| Zaporozhchenko, BS | 1 |
| Shishlov, VI | 1 |
| Bearman, SI | 1 |
| Refsum, SE | 1 |
| Halliday, MI | 1 |
| Campbell, G | 1 |
| McCaigue, M | 1 |
| Rowlands, BJ | 1 |
| Boston, VE | 1 |
| Gehrke, K | 1 |
| Traumann, E | 1 |
| Maier, RV | 1 |
| Hoffmann, H | 1 |
| Markewitz, A | 1 |
| Kreuzer, E | 1 |
| Reichert, K | 1 |
| Jochum, M | 1 |
| Faist, E | 1 |
| Luft, FC | 1 |
| Jarrar, D | 1 |
| Chaudry, IH | 1 |
| Wang, P | 1 |
| Parker, SJ | 1 |
| Brown, D | 1 |
| Kenward, CE | 1 |
| Watkins, PE | 1 |
| Grinëv, MV | 1 |
| Golubeva, AV | 1 |
| Harada, H | 1 |
| Ishizaka, A | 1 |
| Yonemaru, M | 1 |
| Mallick, AA | 1 |
| Hatherill, JR | 1 |
| Zheng, H | 1 |
| Lilly, CM | 1 |
| O'Hanley, PT | 1 |
| Raffin, TA | 1 |
2 reviews available for pentoxifylline and MODS
| Article | Year |
|---|---|
Organ dysfunction following hemorrhage and sepsis: mechanisms and therapeutic approaches (Review).
Topics: Adenosine Triphosphate; Animals; Coloring Agents; Critical Care; Cytokines; Diltiazem; Disease Model | 1999 |
[Multiple organ failure].
Topics: Animals; Anti-Bacterial Agents; Anti-Inflammatory Agents, Non-Steroidal; Controlled Clinical Trials | 2001 |
4 trials available for pentoxifylline and MODS
| Article | Year |
|---|---|
Effects of pentoxifylline on coagulation profile and disseminated intravascular coagulation incidence in Egyptian septic neonates.
Topics: Blood Coagulation; Blood Coagulation Tests; Disseminated Intravascular Coagulation; Double-Blind Met | 2010 |
[Pentoxifylline as adjuvant therapy of multiple organ failure].
Topics: Combined Modality Therapy; Critical Care; Humans; Infusions, Intravenous; Multiple Organ Failure; Pe | 1998 |
Effect of pentoxifylline in severe sepsis: results of a randomized, double-blind, placebo-controlled study.
Topics: APACHE; Double-Blind Method; Female; Humans; Male; Middle Aged; Multiple Organ Failure; Pentoxifylli | 1998 |
Pentoxifylline decreases the incidence of multiple organ failure in patients after major cardio-thoracic surgery.
Topics: Aged; APACHE; Biomarkers; Blood Pressure; Cardiac Output; Cardiac Surgical Procedures; E-Selectin; F | 1998 |
10 other studies available for pentoxifylline and MODS
| Article | Year |
|---|---|
Pentoxifylline attenuates leukocyte-endothelial interactions in a two-hit model of shock and sepsis.
Topics: Animals; Cecum; Cell Communication; Disease Models, Animal; Endothelial Cells; Free Radical Scavenge | 2015 |
Pentoxifylline does not improve outcome in a murine model for the multiple-organ dysfunction syndrome.
Topics: Animals; Cells, Cultured; Cytokines; Dose-Response Relationship, Drug; Double-Blind Method; Mice; Mi | 2005 |
Modeling MODS: what can be learned from animal models of the multiple-organ dysfunction syndrome?
Topics: Animals; Disease Models, Animal; Immunologic Factors; Mice; Multiple Organ Failure; Pentoxifylline; | 2005 |
[Functional state of the liver in patients with an acute destructive pancreatitis in the early postoperative period].
Topics: Adult; Amino Acids; Female; Humans; Liver; Liver Function Tests; Male; Multiple Organ Failure; Pancr | 2005 |
The syndrome of hepatic veno-occlusive disease after marrow transplantation.
Topics: Alprostadil; Biopsy; Bone Marrow Transplantation; Busulfan; Clinical Trials as Topic; Combined Modal | 1995 |
Modulation of TNF alpha and IL-6 in a peritonitis model using pentoxifylline.
Topics: Animals; Blood Pressure; Cecum; Disease Models, Animal; Female; Interleukin-6; Intestinal Perforatio | 1996 |
Pentoxifylline in sepsis.
Topics: Humans; Multiple Organ Failure; Pentoxifylline; Phosphodiesterase Inhibitors; Research Design; Sepsi | 1998 |
A shocking state of affairs.
Topics: Endotoxins; Humans; Multiple Organ Failure; Pentoxifylline; Shock, Hemorrhagic; Tumor Necrosis Facto | 1999 |
Pentoxifylline fails to improve organ dysfunction and survival when used in the resuscitation of a porcine model of haemorrhage and abdominal sepsis.
Topics: Animals; Disease Models, Animal; Dose-Response Relationship, Drug; Female; Hemodynamics; Hemorrhage; | 2000 |
The effects of aminophylline and pentoxifylline on multiple organ damage after Escherichia coli sepsis.
Topics: Albumins; Aminophylline; Animals; Blood Pressure; Bronchoalveolar Lavage Fluid; Edema; Escherichia c | 1989 |